By Fineline Cube 
The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative drug FILSUVEZ (tentative name: birch triterpenes topical gel) in China. This marks the world’s first approved treatment for wounds associated with Dystrophic Epidermolysis Bullosa (DEB) and Junctional Epidermolysis Bullosa (JEB) in patients aged six months and older.
Disease Background
Epidermolysis Bullosa (EB), a rare disease with an estimated 15,000 patients in China, is caused by inherited factors or gene mutations. It is characterized by fragile skin that blisters or erodes easily. The launch of FILSUVEZ in Lecheng (Boao) addresses the previous treatment gap in China, offering an advanced therapeutic option for EB patients.
Product Benefits
FILSUVEZ meets clinical needs by increasing target wound closure rates, shortening healing time, reducing target wound area, decreasing dressing change frequency, alleviating pain during dressing changes, and reducing wound care time for patients and caregivers.
Clinical Trial Results
In the largest global, multi-center, randomized controlled Phase III clinical trial for EB, the birch triterpenes treatment group showed a 44% higher probability of achieving complete target wound closure within 45 days compared to the control gel group. The average time to target wound closure was shortened by 6.8 days.-Fineline Info & Tech